

ENTER PASSWORD:

Welcome to DIALOG

Dialog level 02.09.15D

Last logoff: 28sep02 13:05:08

Logon file001 29sep02 10:45:59

*** ANNOUNCEMENT ***

--As of October 1, 2002, the following files from Cambridge Scientific Abstracts (CSA) will no longer be available: 14, 28, 32, 33, 36, 37, 41, 44, 56, 61, 76, 77, 108, 117, 232, 238, 269, 293, 335. Please enter HELP CSA plus the file number to identify alternative sources of information. Example: HELP CSA 14.

--File 515 D&B Dun's Electronic Business Directory is now online completely updated and redesigned. For details, see HELP NEWS 515.

--File 990 - NewsRoom now contains May 2002 to present records. File 993 - NewsRoom archive contains 2002 records from January 2002-April 2002. To search all 2002 records, BEGIN 990,993 or B NEWS2002.

--Alerts have been enhanced to allow a single Alert profile to be stored and run against multiple files. Duplicate removal is available across files and for up to 12 months. The Alert may be run according to the file's update frequency or according to a custom calendar-based schedule. There are no additional prices for these enhanced features. See HELP ALERT for more information.

--U.S. Patents Fulltext (File 654) has been redesigned with new search and display features. See HELP NEWS 654 for information.

--Connect Time joins DialUnits as pricing options on Dialog. See HELP CONNECT for information.

--CLAIMS/US Patents (Files 340,341, 942) have been enhanced with both application and grant publication level in a single record. See HELP NEWS 340 for information.

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

--Important news for public and academic libraries. See HELP LIBRARY for more information.

--Important Notice to Freelance Authors--
See HELP FREELANCE for more information

For information about the access to file 43 please see Help News43.

NEW FILES RELEASED

***Dialog NewsRoom - Current 3-4 months (File 990)

***Dialog NewsRoom - 2002 Archive (File 993)

***Dialog NewsRoom - 2001 Archive (File 994)

***Dialog NewsRoom - 2000 Archive (File 995)

***TRADEMARKSCAN-Finland (File 679)

***TRADEMARKSCAN-Norway (File 678)

***TRADEMARKSCAN-Sweden (File 675)

WEST

Generate Collection

Print

L1: Entry 36 of 43

File: USPT

Jun 24, 1997

DOCUMENT-IDENTIFIER: US 5641677 A

TITLE: Method of enhancing the immunotherapeutic activity of immune cells by depletion of CD8.sup.+ T cells

Detailed Description Text (12):

The antibody to a lymphocyte surface receptor can be any of a variety of monoclonal antibodies against a surface antigen receptor complex. Useable antibodies include an anti-CD2, anti-CD4, anti-CD5, anti-CD28, anti-CD11b, etc., monoclonal antibody (MoAb). The antibody used in the present invention is preferably an anti-CD3 monoclonal antibody. The antibodies can be used alone or in various combinations with other antibodies. For example, anti-CD3 can be used in combination with anti-CD2, anti-CD4, anti-CD5, anti-CD28, or anti-CD11b, for effective results. Anti-CD3 or anti-CD2 can each be used individually as the antibody in the cultures. The anti-CD3 MoAb can be, but is not limited to, OKT3, WT32, Leu-4, SPV-T3c, RIV9, 64.1, etc. More preferably, the anti-CD3 MoAb is OKT3, which is available from Ortho, a division of Johnson & Johnson.

Detailed Description Text (39):

The observations that either CD4.sup.+ or CD8.sup.+ cells can, under the appropriate conditions, develop LAK activity and that the generation of that LAK activity is regulated by the presence of the reciprocal T cell subset, have implications for protocols for adoptive immunotherapy. For example, under certain conditions it is preferable to have LAK activity mediated by T cells. Thus, the present invention opens the possibility of including T cells with LAK activity in future clinical trials. Such cells could possibly achieve complementary or different antitumor effects than have been observed in conventional protocols.

Other Reference Publication (17):

S. Shu et al., J. Immunol., 1985, 135, 2895, "Adoptive Immunotherapy of a Newly Induced Sarcoma: Immunologic Characteristics of Effector Cells".